Key facts
- Solarea Bio’s last known valuation is $37.0M (Nov 2025).
- It has raised $37.4M across 4 recorded rounds; the latest was Early Stage VC ($9.9M) in Nov 2025.
- Notable investors include Viking Global Investors, Joyance Partners, Olive Tree Capital, S2G Investments, BOLD Capital Partners — 12 tracked in total.
- Solarea Bio has filed 4 Form Ds with the SEC since 2020, most recently Nov 2025 ($9.9M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Solarea Bio
Funding rounds
4 roundsAbout Solarea Bio
Developer of microbiome-based health products designed to address age-related inflammatory conditions and improve overall health. The company offers microbial solutions derived from bacteria and fungi found in fruits and vegetables, supported by proprietary isolation technology and a structured development pipeline, enabling individuals with inflammatory and age-related conditions to manage symptoms and support long-term health.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2017
- Employees
- 19
- Website
- lab.solaria.bio/
- Ownership
- Privately Held (backing)
Solarea Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solarea Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solarea Bio in its N-PORT filings yet. We sweep new filings monthly.